Skip to main content
SpringerLink
Log in

The differential effects of stanozolol on human skin and synovial fibroblastsin vitro: DNA synthesis and receptor binding

  • Published:
Agents and Actions Aims and scope Submit manuscript

Abstract

The anabolic steroid stanozolol stimulates the production of prostaglandin E2 (PGE2) and the matrix metalloproteinases collagenase and stromelysin in human skin fibroblasts but not in rheumatoid synovial fibroblasts. The basis for these differential responses was investigated at the levels of DNA synthesis and steroid receptor binding. Stanozolol inhibited fibroblast growth factor (FGF)-stimulated DNA synthesis in both the skin and synovial fibroblasts, showing that both cell types were capable of responding to the compound. Competitive binding assays indicated that stanozolol bound specifically to both the skin and synovial fibroblasts. Binding of stanozolol to both cell types could be partially displaced by progesterone, indicating that stanozolol binds to the progesterone receptor. Immunocytochemical studies confirmed the presence of progesterone receptors on skin and synovial fibroblasts. However, progesterone failed to elicit any response with respect to collagenase production in either cell type. Nortestosterone, dexamethasone and 17β-oestradiol had no effect on binding of stanozolol to either cell type.

These results indicate that the inhibition of DNA synthesis by stanozolol is elicited through the progesterone receptor. The effects of stanozolol on collagenase and PGE2 production are mediated by a different receptor, present on skin but not synovial fibroblasts, and as yet unidentified.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. J. J. F. Belch, B. McArdle, R. Madhok, K. McLaughlin, H. A. Cappell, C. D. Forbes and A. D. Sturrock,Decreased plasma fibrinolysis in patients with rheumatoid arthritis. Ann. Rheum. Dis.43, 774–779 (1984).

    PubMed  Google Scholar 

  2. P. E. M. Jarrett, M. Morland and N. L. Browse,Treatment of Raynaud's phenomenon by fibrinolytic enhancement. Br. Med. J.2, 523–525 (1978).

    PubMed  Google Scholar 

  3. K. Burnand, G. Clemenson, M. Morland, P. E. M. Jarrett and N. L. Browse,Venous lipodermatosclerosis: Treatment by fibrinolytic enhancement and elastic compression. Br. Med. J.280, 7–11 (1980).

    PubMed  Google Scholar 

  4. J. F. Davidson, M. Lockhead, G. A. McDonald and G. P. McNicol,Fibrinolytic enhancement by stanozolol: A double blind trial. Br. J. Haem.22, 543–559 (1972).

    Google Scholar 

  5. C. Kluft, F. E. Preston, R. G. Malia, R. M. Bertina, G. Wijngaards, M. Greaves, J. H. Verheijen and G. Dooijewaard,Stanozolol-induced changes in fibrinolysis and coagulation in healthy adults. Thromb. Haemost.51(2), 157–164 (1984).

    PubMed  Google Scholar 

  6. J. J. F. Belch, R. Madhok, B. McArdle, K. McLaughlin, C. Kluft, C. D. Forbes and R. D. Sturrock,The effect of increasing fibrinolysis in patients with rheumatoid arthritis: a double blind study of stanozolol. Quart. J. Med.225, 19–27 (1986).

    Google Scholar 

  7. A. J. Ellis, J. K. Wright, T. E. Cawston and B. L. Hazleman,The differential responses of human skin and synovial fibroblasts to stanozolol in vitro: Production of prostaglandin E 2 and matrix metalloproteinases. Agents and Actions35, 232–237 (1992).

    PubMed  Google Scholar 

  8. R. L. Barbieri, H. Lee and K. J. Ryan,Danazol binding to rat androgen, glucocorticoid, progesterone and estrogen receptors: Correlation with biologic activity. Fertility and Sterility31, 182–186 (1979).

    PubMed  Google Scholar 

  9. A. J. M. Audebert,Overview of the mechanism of action of danazol. InRecent Advances in the Management of Endometriosis (Eds. J. A. Rock and K. W. Schweppe), Parthenon, 1988.

  10. J. K. Wright, P. Hughes and N. R. Rowell,Lymphocyte cytotoxicity in systemic sclerosis: no increase on short-term culture with established human cell lines. Ann. Rheum. Dis.41, 414 (1982).

    PubMed  Google Scholar 

  11. D. Gospodarowicz,Biological activity in vivo and in vitro of pituitary and brain fibroblast growth factor. InMediators in Cell Growth and Differentiation (eds. R. J. Ford and A. L. Maizel), pp. 109–134, Raven Press, New York 1985.

    Google Scholar 

  12. R. G. Ham,Growth of normal human cells in defined media. InHormonally Defined Media (Eds. G. Fischer and R. J. Wieser) pp. 16–30, Springer, Berlin 1983.

    Google Scholar 

  13. E. Sher, J. A. Eisman, J. M. Moseley and T. J. Martin,Whole cell uptake and nuclear localisation of 1,25-dihydroxycholecalciferol by breast cancer cells (T47D) in culture. Biochem J.200, 315–320 (1981).

    PubMed  Google Scholar 

  14. T. E. Cawston and A. J. Barrett,A rapid and reproducible assay for collagenase using 1-14 C acetylated collagen. Anal. Biochem.99, 340–345 (1979).

    Article  PubMed  Google Scholar 

  15. C. M. Taylor, B. Blanchard and D. T. Zava,A simple method to determine whole cell uptake of radiolabelled oestrogen and progesterone and their subcellular localisation in breast cancer cell lines in monolayer culture. J. Steroid Biochem.20, 1083–1088 (1984).

    Article  PubMed  Google Scholar 

  16. G. Jenkin, C. I. Cookson and G. D. Thorburn,The interaction of human endometrial and myometrial steroid receptors with danazol. Clin. Endocrinol.19, 377–388 (1983).

    Google Scholar 

  17. D. D. Wood, E. J. Ihrie, C. A. Dinarello and P. L. Cohen,Isolation of an interleukin-1-like factor from human joint effusions. Arth. Rheum.26(8), 975–983 (1983).

    Google Scholar 

  18. D. M. Butler, D. S. Piccoli, P. H. Hart and J. A. Hamilton,Stimulation of human synovial fibroblast DNA synthesis by recombinant human cytokines. J. Rheumatol.15, 1463–1470 (1988).

    PubMed  Google Scholar 

  19. T. Leizer, B. J. Clarris, P. E. Ash, J. van Damme, J. Saklatvala and J. A. Hamilton,Interleukin-1α and interleukin-1β stimulate the plasminogen activator activity and prostaglandin E 2 levels of human synovial cells. Arth. Rheum.30(5), 562–566 (1987).

    Google Scholar 

  20. T. C. Spelsberg, M. L. Graham, N. J. Berg, T. Umehara, E. Riehl, C. B. Coularn and J. N. Ingle,A nuclear binding assay to assess the biological activity of steriod receptors in isolated animal and human tissues. Endocrinology121, 631–644 (1987).

    PubMed  Google Scholar 

  21. A. Guiochon-Mantel, H. Loosfelt, T. Ragot, A. Bailly, M. Atger, M. Misrahi, M. Perricaudet and E. Milgrom,Receptors bound to antiprogestin form abortive complexes with hormone responsive elements. Nature336, 695–698 (1988).

    Article  PubMed  Google Scholar 

  22. R. L. Barbieri and K. J. Ryan,Danazol: Endocrine pharmacology and therapeutic applications. Am. J. Obstet. Gynec.141,

Download references

Author information

Authors and Affiliations

  1. Rheumatology Research Unit, Addenbrooke's Hospital, Hills Road, Box 194, CB2 2QQ, Cambridge, UK

    Alison J. Ellis, Tim E. Cawston & Eleanor J. Mackie

Authors
  1. Alison J. Ellis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tim E. Cawston
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eleanor J. Mackie
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ellis, A.J., Cawston, T.E. & Mackie, E.J. The differential effects of stanozolol on human skin and synovial fibroblastsin vitro: DNA synthesis and receptor binding. Agents and Actions 41, 37–43 (1994). https://doi.org/10.1007/BF01986391

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01986391

Key words

Search

Navigation